Shares fell 7% after quarterly sales missed analyst forecasts and the full-year revenue outlook came in below expectations.
Why Amrize Ltd Stock Fell Today
Amrize Ltd shares fell 7% to $37.55 in trading after the market closed following disappointing sales and a weaker full-year sales outlook. That left a steady earnings result competing with weaker sales signals, so holders must weigh whether pricing can offset cost pressure. about 6.9 million shares traded, about double the usual pace.
What Amrize Ltd Does
Amrize supplies construction materials and building products for infrastructure, commercial and residential projects. That ties its sales to construction activity, where weather and borrowing costs can affect the pace of work.
Amrize Third-Quarter Sales and Earnings
Quarterly revenue came in below what analysts expected for sales, despite rising from a year earlier. Adjusted earnings, which exclude specified items, were unchanged from a year earlier. They exceeded the estimate reported by FactSet, a firm that compiles analyst forecasts.
Amrize Full-Year Sales Outlook
Management’s estimate of full-year sales came in below analyst expectations. It cited rising costs and elevated interest rates, while also pointing to pricing gains and weather-affected construction. Higher borrowing costs can make projects harder to finance, limiting demand for building supplies.
Quick Financial Overview
Amrize is a profitable a large-cap, meaning a business with substantial stock market value. Its market capitalization, the value of all its shares, is $20.54B. It held $729.0M in cash and cash equivalents, meaning cash the company can spend, as of June 30, 2026.
Amrize Profit and Cost Savings
Net income, the profit remaining after expenses, rose 3.3% to $558 million. The company’s cost-saving program delivered $73 million in savings year-to-date. Those savings help protect profit when fuel, freight and other operating costs rise.
Amrize Stock Is down 29% Over Six Months
Amrize shares trade near their lowest price of the past year after a long decline. Today’s drop stands out because the last daily move this large was fifty-seven sessions ago. The latest results interrupt the stock’s recent recovery rather than extend it.
Amrize Completes $1 Billion Share Repurchase
Amrize completed its $1 billion share repurchase, a program in which a company buys its own shares. It bought back 22,446,667 shares, equal to 3.96% of the company’s issued shares, and the board intends to cancel them. Cancellation removes the bought-back shares, leaving each remaining share with a larger ownership stake in the business.
Conclusion
Management’s results webcast on Thursday, October 29, gives holders the next chance to hear how it plans to balance pricing and costs. Evidence that higher prices are sticking would strengthen the recovery case. Signs that customers are delaying more projects would make that path harder.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

